Results 311 to 320 of about 664,442 (399)

Tenecteplase in acute ischemic stroke: a new era in thrombolysis. [PDF]

open access: yesArq Neuropsiquiatr
Silva GS   +3 more
europepmc   +1 more source

Transendocardial injection of expanded autologous CD34+ cells after myocardial infarction: Design of the EXCELLENT trial

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1455-1463, April 2025.
Abstract Aims The extent of irreversible cardiomyocyte necrosis after acute myocardial infarction (AMI) is a major determinant of residual left ventricular (LV) function and clinical outcome. Cell therapy based on CD34+ cells has emerged as an option to help repair the myocardium and to improve outcomes.
Jerome Roncalli   +17 more
wiley   +1 more source

Phenotyping patients with chronic obstructive pulmonary disease and heart failure

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 900-911, April 2025.
Central illustration. Abbreviations: ACEi, angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNi, angiotensin‐receptor‐neprilysin inhibitor; CI, confidence interval; COPD, chronic obstructive pulmonary disease; CRT, cardiac resynchronization therapy; CV, cardiovascular; EF, ejection fraction; eGFR, estimated glomerular ...
Peter Moritz Becher   +12 more
wiley   +1 more source

Comparative performance of risk prediction indices for mortality or readmission following heart failure hospitalization

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1227-1236, April 2025.
Comparative performance of 7 risk prediction indices in patients hospitalized for heart failure. In this cohort of 1206 patients, the LENT index offered the greatest discrimination, calibration, and overall accuracy in predicting 30‐day composite all‐cause mortality or readmission following hospitalization for heart failure.
Tauben Averbuch   +8 more
wiley   +1 more source

Unmet Needs in Acute Ischemic Stroke: Overcoming Recalcitrant Clots. [PDF]

open access: yesCardiol Rev
Mirza M   +4 more
europepmc   +1 more source

Long‐term cardiovascular outcomes of immune checkpoint inhibitor‐related myocarditis: A large single‐centre analysis

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1237-1245, April 2025.
Abstract Aims Immune checkpoint inhibitors (ICI) are the cornerstone of modern oncology; however, side effects such as ICI‐related myocarditis (irM) can be fatal. Recently, Bonaca proposed criteria for irM; however, it is unknown if they correlate well with cardiovascular (CV) ICI‐related adverse events.
Lorenzo Braghieri   +12 more
wiley   +1 more source

Epidemiology of hospitalized heart failure in France based on national data over 10 years, 2012–2022

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1283-1294, April 2025.
Abstract Aims We aim to describe the incidence of HF hospitalization in France in the post‐pandemic era, the prevalence of HF cases and patients' characteristics, management and outcomes while focusing on sex, age and socio‐economic differences and to analyse time‐trends between 2012 and 2022.
Valérie Olié   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy